Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Neurobiol Aging. 2015 Jul 16;36(11):2963–2971. doi: 10.1016/j.neurobiolaging.2015.07.016

Table 1.

Characteristics of control and CAA subjects examined in this study

Case ID Age Gender ADa CAA Group
1248 63 M A3B3C3 Severe AD+CAA
1023 88 M A3B3C3 Severe AD+CAA
1186 85 M A3B3C3 Severe AD+CAA
919 82 M A3B3C3 Moderate AD+CAA
1150 66 F A1B2C1 Severe CAA
821 89 M A1B1C1 Severe CAA
1138 75 F A0B0C0 Severe CAA
458 80 M A0B1C0 Severe CAA
753 77 F A1B1C1 Severe CAA
960 68 M A1B1C1 Moderate CAA
287 66 M A0B0C0 Mild Control
873 74 F A1B1C0 Absent Control
792 71 M A0B0C0 Absent Control
326 >90 M A1B1C0 Absent Control
373 80 F A1B1C0 Absent Control
a

The ABC scoring scheme (Montine et al., 2012): the A represents the assessment of Amyloid burden (by the modified Thal scoring scheme); the B represents the Braak stage (consolidated from 6 tiers to 3) and the C represents the neuritic plaque score.